Satoru Kitazono1, Yutaka Fujiwara2, Koji Tsuta3, Hirofumi Utsumi4, Shintaro Kanda4, Hidehito Horinouchi4, Hiroshi Nokihara4, Noboru Yamamoto5, Shinji Sasada6, Shun-ichi Watanabe7, Hisao Asamura7, Tomohide Tamura4, Yuichiro Ohe4. 1. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 2. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Experimental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital, Tokyo, Japan. Electronic address: yutakafu@ncc.go.jp. 3. Department of Pathology, National Cancer Center Hospital, Tokyo, Japan. 4. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. 5. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Experimental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. 7. Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS: A total of 79 patients with NSCLC at our institution with available biopsy samples and resected specimens were retrospectively enrolled in the present study. PD-L1 expression was assessed by immunohistochemistry and scored using the hybrid scoring method. The concordance rates for the expression of PD-L1 between the 2 samples were analyzed. RESULTS: The pathologic stage of the patients (51 men, 28 women; median age, 68 years) was stage I in 37, stage II in 18, and stage III in 24. The diagnostic procedures included transbronchial biopsy in 59, transbronchial needle aspiration biopsy in 14, and computed tomography (CT)-guided needle biopsy in 6. The positivity rate of PD-L1 in these samples was 38.0% (27 transbronchial biopsies, 6 transbronchial needle aspiration biopsies, 3 CT-guided needle biopsies) versus 35.4% in the resected specimens. The median hybrid score was 0 (range, 0-170), and the mean score was 28.7 ± 43.4. Comparing the biopsy samples and resected specimens with a score of ≥ 1 as positive for PD-L1 staining, 6 tumors were discordant for PD-L1 expression and 73 were concordant, for a concordance rate of 92.4% and κ value of 0.8366. CONCLUSION: PD-L1 status showed good concordance between the biopsy samples and resected specimens. These small samples, even those derived from transbronchial needle aspiration biopsies, appear adequate for the assessment of PD-L1 expression.
BACKGROUND: Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS: A total of 79 patients with NSCLC at our institution with available biopsy samples and resected specimens were retrospectively enrolled in the present study. PD-L1 expression was assessed by immunohistochemistry and scored using the hybrid scoring method. The concordance rates for the expression of PD-L1 between the 2 samples were analyzed. RESULTS: The pathologic stage of the patients (51 men, 28 women; median age, 68 years) was stage I in 37, stage II in 18, and stage III in 24. The diagnostic procedures included transbronchial biopsy in 59, transbronchial needle aspiration biopsy in 14, and computed tomography (CT)-guided needle biopsy in 6. The positivity rate of PD-L1 in these samples was 38.0% (27 transbronchial biopsies, 6 transbronchial needle aspiration biopsies, 3 CT-guided needle biopsies) versus 35.4% in the resected specimens. The median hybrid score was 0 (range, 0-170), and the mean score was 28.7 ± 43.4. Comparing the biopsy samples and resected specimens with a score of ≥ 1 as positive for PD-L1 staining, 6 tumors were discordant for PD-L1 expression and 73 were concordant, for a concordance rate of 92.4% and κ value of 0.8366. CONCLUSION:PD-L1 status showed good concordance between the biopsy samples and resected specimens. These small samples, even those derived from transbronchial needle aspiration biopsies, appear adequate for the assessment of PD-L1 expression.
Authors: Paul Zarogoulidis; Vasilis Papadopoulos; Elena Maragouli; George Papatsibas; Chrysanthi Sardeli; Yan-Gao Man; Chong Bai; Haidong Huang Journal: Transl Lung Cancer Res Date: 2018-02
Authors: Emily B Tsai; Kelsey Pomykala; Kathleen Ruchalski; Scott Genshaft; Fereidoun Abtin; Antonio Gutierrez; Hyun J Kim; Alice Li; Carlos Adame; Ashkan Jalalian; Brian Wolf; Edward B Garon; Jonathan W Goldman; Robert Suh Journal: Radiology Date: 2017-12-12 Impact factor: 11.105
Authors: Thomas J Gniadek; Qing Kay Li; Ellen Tully; Samit Chatterjee; Sridhar Nimmagadda; Edward Gabrielson Journal: Mod Pathol Date: 2017-01-06 Impact factor: 7.842
Authors: Matthew Evans; Brendan O'Sullivan; Frances Hughes; Tina Mullis; Matthew Smith; Nicola Trim; Philippe Taniere Journal: Pathol Oncol Res Date: 2018-09-17 Impact factor: 3.201
Authors: Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström Journal: Acta Cytol Date: 2021-07-07 Impact factor: 2.319